A further 16 participants withdrew during the trial,
leaving a protocol correct population of 124.
Figure 1 summarises the flow of patients through the study.
Only two patients (both in the placebo arm) were withdrawn owing to adverse events—one developed a blotchy erythematous rash;
the other developed diarrhoea and vomiting, headache, fever, and worseningofasthma.Diseaseseveritywascomparableinthetwo groups at baseline (table 1).